Moderate-to-Severe Thyroid Eye Disease research hub

A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thyroid Eye Disease

This study is looking at a new medicine called Satralizumab for people with moderate to severe Thyroid Eye Disease. It aims to see if the medicine can reduce bulging eyes (proptosis) and improve symptoms while being safe to use.